Soumen Khatua1, Laurence J N Cooper2, David I Sandberg3,4, Leena Ketonen5, Jason M Johnson5, Michael E Rytting1, Diane D Liu6, Heather Meador1, Prashant Trikha7, Robin J Nakkula7, Gregory K Behbehani7, Dristhi Ragoonanan1, Sumit Gupta1, Aikaterini Kotrotsou8, Tagwa Idris9, Elizabeth J Shpall10, Katy Rezvani10, Rivka Colen11,12, Wafik Zaky1, Dean A Lee7, Vidya Gopalakrishnan1. 1. Department of Pediatrics, MD Anderson Cancer Center, Houston. 2. Ziopharm Oncology and MD Anderson Cancer Center, Houston. 3. Department of Neurosurgery, MD Anderson Cancer Center, Houston. 4. Department of Neurosurgery, McGovern Medical School/University of Texas Health Science Center, Houston. 5. Department of Diagnostic Imaging, MD Anderson Cancer Center, Houston. 6. Department of Biostatistics, University of Texas MD Anderson Cancer center. 7. Department of Hematology, Oncology and BMT, Nationwide Children's Hospital, Columbus, Ohio and Department of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 8. Department of Cancer Systems Imaging, MD Anderson Cancer Center, Houston. 9. Department of Radiology, Harvard Medical School. 10. Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston. 11. Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 12. Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Recurrent pediatric medulloblastoma and ependymoma have a grim prognosis. We report a first-in-human, phase I study of intraventricular infusions of ex vivo expanded autologous natural killer (NK) cells in these tumors, with correlative studies. METHODS: Twelve patients were enrolled, 9 received protocol therapy up to 3 infusions weekly, in escalating doses from 3 × 106 to 3 × 108 NK cells/m2/infusion, for up to 3 cycles. Cerebrospinal fluid (CSF) was obtained for cellular profile, persistence, and phenotypic analysis of NK cells. Radiomic characterization on pretreatment MRI scans was performed in 7 patients, to develop a non-invasive imaging-based signature. RESULTS: Primary objectives of NK cell harvest, expansion, release, and safety of 112 intraventricular infusions of NK cells were achieved in all 9 patients. There were no dose-limiting toxicities. All patients showed progressive disease (PD), except 1 patient showed stable disease for one month at end of study follow-up. Another patient had transient radiographic response of the intraventricular tumor after 5 infusions of NK cell before progressing to PD. At higher dose levels, NK cells increased in the CSF during treatment with repetitive infusions (mean 11.6-fold). Frequent infusions of NK cells resulted in CSF pleocytosis. Radiomic signatures were profiled in 7 patients, evaluating ability to predict upfront radiographic changes, although they did not attain statistical significance. CONCLUSIONS: This study demonstrated feasibility of production and safety of intraventricular infusions of autologous NK cells. These findings support further investigation of locoregional NK cell infusions in children with brain malignancies.
BACKGROUND: Recurrent pediatric medulloblastoma and ependymoma have a grim prognosis. We report a first-in-human, phase I study of intraventricular infusions of ex vivo expanded autologous natural killer (NK) cells in these tumors, with correlative studies. METHODS: Twelve patients were enrolled, 9 received protocol therapy up to 3 infusions weekly, in escalating doses from 3 × 106 to 3 × 108 NK cells/m2/infusion, for up to 3 cycles. Cerebrospinal fluid (CSF) was obtained for cellular profile, persistence, and phenotypic analysis of NK cells. Radiomic characterization on pretreatment MRI scans was performed in 7 patients, to develop a non-invasive imaging-based signature. RESULTS: Primary objectives of NK cell harvest, expansion, release, and safety of 112 intraventricular infusions of NK cells were achieved in all 9 patients. There were no dose-limiting toxicities. All patients showed progressive disease (PD), except 1 patient showed stable disease for one month at end of study follow-up. Another patient had transient radiographic response of the intraventricular tumor after 5 infusions of NK cell before progressing to PD. At higher dose levels, NK cells increased in the CSF during treatment with repetitive infusions (mean 11.6-fold). Frequent infusions of NK cells resulted in CSF pleocytosis. Radiomic signatures were profiled in 7 patients, evaluating ability to predict upfront radiographic changes, although they did not attain statistical significance. CONCLUSIONS: This study demonstrated feasibility of production and safety of intraventricular infusions of autologous NK cells. These findings support further investigation of locoregional NK cell infusions in children with brain malignancies.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Martin Benesch; Martin Mynarek; Hendrik Witt; Monika Warmuth-Metz; Torsten Pietsch; Brigitte Bison; Stefan M Pfister; Kristian W Pajtler; Marcel Kool; Ulrich Schüller; Klaus Pietschmann; Björn-Ole Juhnke; Stephan Tippelt; Gudrun Fleischhack; Irene Schmid; Christof M Kramm; Peter Vorwerk; Andreas Beilken; Carl Friedrich Classen; Pablo Hernáiz Driever; Gabriele Kropshofer; Thomas Imschweiler; Andreas Lemmer; Rolf-Dieter Kortmann; Stefan Rutkowski; Katja von Hoff Journal: Oncologist Date: 2019-03-08
Authors: M Iv; M Zhou; K Shpanskaya; S Perreault; Z Wang; E Tranvinh; B Lanzman; S Vajapeyam; N A Vitanza; P G Fisher; Y J Cho; S Laughlin; V Ramaswamy; M D Taylor; S H Cheshier; G A Grant; T Young Poussaint; O Gevaert; K W Yeom Journal: AJNR Am J Neuroradiol Date: 2018-12-06 Impact factor: 3.825
Authors: Kristian W Pajtler; Stephen C Mack; Vijay Ramaswamy; Christian A Smith; Hendrik Witt; Amy Smith; Jordan R Hansford; Katja von Hoff; Karen D Wright; Eugene Hwang; Didier Frappaz; Yonehiro Kanemura; Maura Massimino; Cécile Faure-Conter; Piergiorgio Modena; Uri Tabori; Katherine E Warren; Eric C Holland; Koichi Ichimura; Felice Giangaspero; David Castel; Andreas von Deimling; Marcel Kool; Peter B Dirks; Richard G Grundy; Nicholas K Foreman; Amar Gajjar; Andrey Korshunov; Jonathan Finlay; Richard J Gilbertson; David W Ellison; Kenneth D Aldape; Thomas E Merchant; Eric Bouffet; Stefan M Pfister; Michael D Taylor Journal: Acta Neuropathol Date: 2016-11-17 Impact factor: 17.088
Authors: Roger Sun; Théophraste Henry; Adrien Laville; Alexandre Carré; Anthony Hamaoui; Sophie Bockel; Ines Chaffai; Antonin Levy; Cyrus Chargari; Charlotte Robert; Eric Deutsch Journal: J Immunother Cancer Date: 2022-07 Impact factor: 12.469
Authors: Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz Journal: Transplant Cell Ther Date: 2020-09-29
Authors: Dristhi Ragoonanan; Sajad J Khazal; Hisham Abdel-Azim; David McCall; Branko Cuglievan; Francesco Paolo Tambaro; Ali Haider Ahmad; Courtney M Rowan; Cristina Gutierrez; Keri Schadler; Shulin Li; Matteo Di Nardo; Linda Chi; Alison M Gulbis; Basirat Shoberu; Maria E Mireles; Jennifer McArthur; Neena Kapoor; Jeffrey Miller; Julie C Fitzgerald; Priti Tewari; Demetrios Petropoulos; Jonathan B Gill; Christine N Duncan; Leslie E Lehmann; Sangeeta Hingorani; Joseph R Angelo; Rita D Swinford; Marie E Steiner; Fiorela N Hernandez Tejada; Paul L Martin; Jeffery Auletta; Sung Won Choi; Rajinder Bajwa; Natalie Dailey Garnes; Partow Kebriaei; Katayoun Rezvani; William G Wierda; Sattva S Neelapu; Elizabeth J Shpall; Selim Corbacioglu; Kris M Mahadeo Journal: Nat Rev Clin Oncol Date: 2021-02-19 Impact factor: 65.011
Authors: Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares Journal: Curr Treat Options Oncol Date: 2021-07-30